Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Inverness Acquires Advantage Diagnostics

By Labmedica staff writers
Posted on 30 Jun 2004
In a transaction that will expand the company's intellectual property, Inverness Medical Innovations, Inc. More...
(Waltham, MA, USA) has acquired through a merger transaction all of the stock of Advantage Diagnostics Corp. (ADC, Sunnyvale, CA, USA) for U.S.$2.4 million in cash and a pay-off of ADC debt of $210,000.

Avantage Diagnostics is a lateral flow diagnostic company that specializes in rapid test development and component manufacturing. The company was formed in 1998 by Dr. David Charlton, inventor of one of the key families of lateral flow patents central to the rapid diagnostic industry. Advantage Diagnostics recently developed for Inverness' Applied Biotch (ABI) unit a proprietary drugs-of-abuse test system that combines greatly improved test performance and accuracy with increased efficiency in production and lower manufacturing costs. The acquisition eliminates a future royalty stream related to that product line payable by ABI to ADC under a license agreement.

Inverness Medical Innovations is a global developer of diagnostic devices and is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of professional diagnostic and consumer applications, with a focus on women's health, cardiology, and infectious disease.




Related Links:
Inverness Medical Innovations

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.